Protective Efficacy of Centralized and Polyvalent Envelope Immunogens in an Attenuated Equine Lentivirus Vaccine

English version České info

Our best effort for containment of the global HIV epidemic is the development of a broadly protective vaccine. Current research has focused on vaccines that can generate a protective immune response against numerous strains of the virus. For this reason, vaccines with centralized HIV genes as immunogens, which merge HIV genetic information and potentially protect against multiple viral strains in a single inoculation, are an increasing area of interest to the field. Existing published studies have not evaluated centralized immunogens in the context of attenuated vaccines, which to date, have demonstrated the highest level of vaccine protection in lentiviral studies. Furthermore, centralized immunogen studies have also not included protective efficacy findings accomplished through challenge with highly pathogenic virus strains. In this study we not only examine the immunogenicity of these immunogens in an animal model, but we also for the first time evaluate the ability of centralized immunogens to induce protection against virulent virus challenge.

Vyšlo v časopise: Protective Efficacy of Centralized and Polyvalent Envelope Immunogens in an Attenuated Equine Lentivirus Vaccine. PLoS Pathog 11(1): e32767. doi:10.1371/journal.ppat.1004610
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004610

Souhrn

Zdroje

1. GaschenB, TaylorJ, YusimK, FoleyB, GaoF, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354–2360.

2. AnastassopoulouCG, KostrikisLG (2006) Global genetic variation of HIV-1 infection. Curr HIV Res 4: 365–373.

3. BranderC, FrahmN, WalkerBD (2006) The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 18: 430–437.

4. KorberB, GaschenB, YusimK, ThakallapallyR, KesmirC, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. BrMedBull 58: 19–42.

5. MullinsJI, JensenMA (2006) Evolutionary dynamics of HIV-1 and the control of AIDS. Curr Top Microbiol Immunol 299: 171–192.

6. LiaoHX, TsaoCY, AlamSM, MuldoonM, VandergriftN, et al. (2013) Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87: 4185–4201.

7. MullinsJI, NickleDC, HeathL, RodrigoAG, LearnGH (2004) Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines 3: S151–159.

8. NickleDC, JensenMA, GottliebGS, ShrinerD, LearnGH, et al. (2003) Consensus and ancestral state HIV vaccines. Science 299: 1515–1518 author reply 1515-1518.

9. GaoF, WeaverEA, LuZ, LiY, LiaoHX, et al. (2005) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79: 1154–1163.

10. Doria-RoseNA, LearnGH, RodrigoAG, NickleDC, LiF, et al. (2005) Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79: 11214–11224.

11. KotheDL, DeckerJM, LiY, WengZ, Bibollet-RucheF, et al. (2007) Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360: 218–234.

12. KotheDL, LiY, DeckerJM, Bibollet-RucheF, ZammitKP, et al. (2006) Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352: 438–449.

13. SantraS, MuldoonM, WatsonS, BuzbyA, BalachandranH, et al. (2012) Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428: 121–127.

14. SantraS, KorberBT, MuldoonM, BarouchDH, NabelGJ, et al. (2008) A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A 105: 10489–10494.

15. LiaoHX, SutherlandLL, XiaSM, BrockME, ScearceRM, et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268–282.

16. GaoF, LiaoHX, HahnBH, LetvinNL, KorberBT, et al. (2007) Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 5: 572–577.

17. WeaverEA, LuZ, CamachoZT, MoukdarF, LiaoHX, et al. (2006) Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 80: 6745–6756.

18. EugeneHS, Pierce-PaulBR, CragioJK, RossTM (2013) Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virol J 10: 102.

19. McburneySP, RossTM (2009) Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 27: 4337–4349.

20. Montelaro RC, Ball JM, Rushlow K (1993) Equine retroviruses. In: Levy JA, editor. The Retroviridae. New York, N.Y.: Plenum Press. pp. 257–360.

21. HarroldSM, CookSJ, CookRF, RushlowKE, IsselCJ, et al. (2000) Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 74: 3112–3121.

22. HammondSA, LiF, MckeonBMSr, CookSJ, IsselCJ, et al. (2000) Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 74: 5968–5981.

23. KonoY, HirasawaK, FukunagaY, TaniguchiT (1976) Recrudesence of equine infectious anemia by treatment with immunosuppressive drugs. Nat Inst Anim Hlth Quart 16: 8–15.

24. CraigoJK, MontelaroRC (2013) Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity. Viruses 5: 2963–2976.

25. CraigoJK, MontelaroRC (2011) Equine Infectious Anemia Virus Infection and Immunity: Lessons for Aids Vaccine Development. Future Virol 6: 139–142.

26. Craigo JK, Montelaro RC (2008) Equine Infectious Anemia Virus (Retroviridae). Encyclopedia of Virology. Third ed. Oxford: Elsevier. pp. 167–174.

27. Craigo JK, Montelaro RC (2010) Lentivirus Tropism and Disease. In: Desport M, editor. Lentiviruses and Macrophages: Molecular and Cellular Interactions: Horizon Academic Press. pp. 1–23.

28. CraigoJK, EzzelarabC, CookSJ, ChongL, HorohovD, et al. (2013) Envelope determinants of equine lentiviral vaccine protection. PLoS ONE 8: e66093.

29. CraigoJK, MontelaroRC (2010) EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr HIV Res 8: 81–86.

30. MontelaroRC, ColeKS, HammondSA (1998) Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS ResHumRetroviruses 14 Suppl 3: S255–S259.

31. CraigoJK, DurkinS, SturgeonTJ, TagmyerT, CookSJ, et al. (2007) Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 25: 834–845.

32. CraigoJK, LiF, SteckbeckJD, DurkinS, HoweL, et al. (2005) Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 79: 2666–2677.

33. LiF, CraigoJK, HoweL, SteckbeckJD, CookS, et al. (2003) A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 77: 7244–7253.

34. CraigoJK, ZhangB, BarnesS, TagmyerTL, CookSJ, et al. (2007) Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A 104: 15105–15110.

35. MontelaroRC, WigzellH (1995) AIDS 1995. Vaccines and immunology: overview. AIDS 9 Suppl A: S111–S112.

36. MillsJ, DesrosiersRC, RudE, AlmondN (2000) Live Attenuated HIV Vaccines: A Proposal for Further Research and Development. AIDS ResHumRetroviruses 16: 1453–1461.

37. UhlEW, Heaton-JonesTG, PuR, YamamotoJK (2002) FIV vaccine development and its importance to veterinary and human medicine: a review. FIV vaccine 2002 update and review. VetImmunolImmunopathol 90: 113–132.

38. KoffWC, JohnsonPR, WatkinsDI, BurtonDR, LifsonJD, et al. (2006) HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7: 19–23.

39. CraigoJK, BarnesS, CookSJ, IsselCJ, MontelaroRC (2010) Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease. Vaccine 28: 8095–8104.

40. TagmyerTL, CraigoJK, CookSJ, EvenDL, IsselCJ, et al. (2008) Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol 82: 4052–4063.

41. TagmyerTL, CraigoJK, CookSJ, IsselCJ, MontelaroRC (2007) Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J Gen Virol 88: 1324–1336.

42. LerouxC, CraigoJK, IsselCJ, MontelaroRC (2001) Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 75: 4570–4583.

43. LerouxC, IsselC, MontelaroRC (1997) Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 71: 9627–9639.

44. CraigoJK, SturgeonTJ, CookSJ, IsselCJ, LerouxC, et al. (2006) Apparent elimination of EIAV ancestral species in a long-term inapparent carrier. Virology 344: 340–353.

45. CookRF, CookSJ, BergerSL, LerouxC, GhabrialNN, et al. (2003) Enhancement of equine infectious anemia virus virulence by identification and removal of suboptimal nucleotides. Virology 313: 588–603.

46. CraigoJK, EzzelarabC, MontelaroRC (2012) Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus. J Virol Methods 185: 221–227.

47. HoweL, LerouxC, IsselCJ, MontelaroRC (2002) Equine Infectious Anemia Virus Envelope Evolution In Vivo during Persistent Infection Progressively Increases Resistance to In Vitro Serum Antibody Neutralization as a Dominant Phenotype. The Journal of Virology 76: 10588.

48. LiF, PufferBA, MontelaroRC (1998) The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol 72: 8344–8348.

49. LichtensteinDL, IsselCJ, MontelaroRC (1996) Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J Virol 70: 3346–3354.

50. IsselCJ, HorohovDW, LeaDF, AdamsWVJr, HagiusSD, et al. (1992) Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 66: 3398–3408.

51. HammondSA, CookSJ, LichtensteinDL, IsselCJ, MontelaroRC (1997) Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71: 3840–3852.

52. WeaverEA, CamachoZT, GaoF (2010) Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. AIDS Res Hum Retroviruses 26: 577–584.

53. GilesBM, BisselSJ, DealmeidaDR, WileyCA, RossTM (2012) Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol 19: 128–139.

54. GilesBM, CrevarCJ, CarterDM, BisselSJ, Schultz-CherryS, et al. (2012) A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205: 1562–1570.

55. GilesBM, RossTM (2012) Computationally optimized antigens to overcome influenza viral diversity. Expert Rev Vaccines 11: 267–269.

56. GilesBM, RossTM (2011) A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29: 3043–3054.

57. KotheDL, DeckerJM, LiY, WengZ, Bibollet-RucheF, et al. (2007) Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360: 218–234.

58. Swofford DL (2001) PAUP: Phylogenetic Analysis Using Parsimony and Other Methods. Sunderlan, MA: Sinauer Associates.

59. LerouxC, CadoreJL, MontelaroRC (2004) Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us? Vet Res 35: 485–512.

60. CookRF, CookSJ, LiFL, MontelaroRC, IsselCJ (2002) Development of a multiplex real-time reverse transcriptase-polymerase chain reaction for equine infectious anemia virus (EIAV). J Virol Methods 105: 171–179.

61. LiuC, CookFR, CookSJ, CraigoJK, EvenDL, et al. (2012) The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies. Vet Immunol Immunopathol 148: 302–310.

62. RamakersC, RuijterJM, DeprezRH, MoormanAF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62–66.

63. LivakKJ, SchmittgenTD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25: 402–408.